Verrica Pharmaceuticals To Report Fourth Quarter And Full Year 2024 Financial Results And Provide A Corporate Update On March 11, 2025

(MENAFN- GlobeNewsWire - Nasdaq) WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or“the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update.

Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.

A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, , or by clicking here . A replay of the webcast will be archived on Verrica's website for 90 days following the event.

About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts, one of the largest remaining unmet needs in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit .

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John J Kirby
Interim Chief Financial Officer
...

Kevin Gardner
LifeSci Advisors
...

Chris Calabrese
LifeSci Advisors
...

MENAFN03032025004107003653ID1109269896